ACADIA Pharmaceuticals

World Rank (Jan-05-2024)

2,957

Market Cap (Jan-05-2024)

4.917 Billion USD

World Rank (Jul-30-2023)

3,125

Market Cap (Jul-30-2023)

4.723 Billion USD

World Rank (Jan-07-2022)

4,217

Market Cap (Jan-07-2022)

3.631 Billion USD

World Rank (Jan-01-2021)

1,913

Market Cap (Jan-01-2021)

8.499 Billion USD

Headquarters Country

USA

Nasdaq / NYSE Code

ACAD

Market Cap (Mar-08-2026)

3.78

Employee Count

513

Employee Count as of Date

As on 2022

Headquarters City/State

California

World Region

Americas

World Subregion

Northern America

Annual Revenue in USD

517 Million USD

Annual Operating Income in USD

-223 Million USD

Annual Net Income in USD

-215 Million USD

Annual Results for Period Ending

Dec-2022 ending year

Total Assets in USD

587 Million USD

Total Liabilities in USD

187 Million USD

Total Equity in USD

400 Million USD

Balance Sheet for Period Ending

Dec-2022 ending year

Business Sector

Company Website

ACADIA PHARMACEUTICALS INC

Wikipedia

Yahoo

Yahoo @ Nasdaq

Company Profile

Acadia Pharmaceuticals is a Healthcare and Pharmaceutical company. The company is of food and drug administration for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Around 8 million people in the United States are living with dementia and studies suggest that approximately 30% of people with dementia, 2.4 million people, experience dementia-related hallucinations and delusion. The headquarters is in USA.

Annual Results Summary

ACADIA PHARMACEUTICALS - Annual Results Summary - in Million USD

Year Ending:	Total Revenue	Operating Income	Net Income
Dec-2022	517	-223 (Loss)	-215 (Loss)
Dec-2021	484	-170 (Loss)	-167 (Loss)
Dec-2020	441.8	(286.6) (Loss)	(281.6) (Loss)
Dec-2019	339.1	(246.5) (Loss)	(235.3) (Loss)
Dec-2018	223.8	(247.4) (Loss)	(245.2) (Loss)
Dec-2017	124.9	(292.4) (Loss)	(289.4) (Loss)